您的位置: 首页 > 农业专利 > 详情页

СОЕДИНЕНИЯ ИНГИБИТОРА ТИРОЗИНКИНАЗЫ И ИХ ПРИМЕНЕНИЕ
专利权人:
НОВАРТИС АГ (CH)
发明人:
ТИДТ Ральф (CH),БАКЛЕР Алан (US),ХАРБИНСКИ Фред (US),САНГХАВИ Снеха (US),ДЖЕФФРИ Дуглас (US),УИЛСОН Кристофер (US)
申请号:
RU2014143213
公开号:
RU2014143213A
申请日:
2013.04.01
申请国别(地区):
RU
年份:
2016
代理人:
摘要:
A pharmaceutical combination comprising (i) a MET inhibitor and (ii) an FGFR inhibitor, or a pharmaceutically acceptable salt of the aforementioned compounds, respectively, or a prodrug thereof, respectively, and at least one pharmaceutically acceptable carrier. A pharmaceutical combination according to claim 1 for the simultaneous, separate or sequential use of components (i) and (ii). The pharmaceutical combination according to claim 1 in the form of a fixed combination. The pharmaceutical combination according to claim 1 in the form of a dosage form or a combination kit for combined administration wherein the FGFR tyrosine kinase inhibitor and the MTE tyrosine kinase inhibitor can be administered independently of each other simultaneously or separately during the time intervals, When these time intervals allow the components of the compound to manifest joint activity. A pharmaceutical combination according to any one of 1-4, wherein the MTE tyrosine kinase inhibitor is selected from the group consisting of (E) -2- (1- (3 - ((7-fluoroquinolin-6-yl) methyl) imidazo [1,2-b] pyridazin-6- yl) ethylidene) hydrazinecarboxamide and 2-fluoro-N-methyl-4 - [(7-quinolin-6-ylmethyl) imidazo [1,2-b] triazin-2-yl] benzamide, or a pharmaceutically acceptable salt or prodrug forms of these compounds, and the FGR-R tyrosine kinase inhibitor is 3- (2,6-dichloro-3,5-dimethoxy-phenyl) -1- {6- [4- (4-ethylpiperazin-1-yl) -phenylamino] -pyrimidin-4-yl} -1-methyl-urea, or a pharmaceutically acceptable salt or prodrugform of said compound. A pharmaceutical combination according to any one of 1-4 containing an additional agent, or a pharmaceutically acceptable salt or prodrug thereof. A pharmaceutical combination according to any one of 1-4, containing an amount that is c1. Фармацевтическая комбинация, содержащая (i) ингибитор MET и (ii) ингибитор FGFR, либо фармацевтически приемлемую соль вышеуказанных соединений, соответственно, либо их пролекарственную форму, соответственно, и, по край
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充